DNA Hypomethylation Affects Cancer-Related Biological Functions and Genes Relevant in Neuroblastoma Pathogenesis

Neuroblastoma (NB) pathogenesis has been reported to be closely associated with numerous genetic alterations. However, underlying DNA methylation patterns have not been extensively studied in this developmental malignancy. Here, we generated microarray-based DNA methylation profiles of primary neuroblastic tumors. Stringent supervised differential methylation analyses allowed us to identify epigenetic changes characteristic for NB tumors as well as for clinical and biological subtypes of NB. We observed that gene-specific loss of DNA methylation is more prevalent than promoter hypermethylation. Remarkably, such hypomethylation affected cancer-related biological functions and genes relevant to NB pathogenesis such as CCND1, SPRR3, BTC, EGF and FGF6. In particular, differential methylation in CCND1 affected mostly an evolutionary conserved functionally relevant 3′ untranslated region, suggesting that hypomethylation outside promoter regions may play a role in NB pathogenesis. Hypermethylation targeted genes involved in cell development and proliferation such as RASSF1A, POU2F2 or HOXD3, among others. The results derived from this study provide new candidate epigenetic biomarkers associated with NB as well as insights into the molecular pathogenesis of this tumor, which involves a marked gene-specific hypomethylation.

[1]  S. Ahn,et al.  Expression of SPRR3 is associated with tumor cell proliferation in less advanced stages of breast cancer , 2012, Breast Cancer Research and Treatment.

[2]  J. Thomson,et al.  Thermal Stability of Fibroblast Growth Factor Protein Is a Determinant Factor in Regulating Self‐Renewal, Differentiation, and Reprogramming in Human Pluripotent Stem Cells , 2012, Stem cells.

[3]  R. Siebert,et al.  Distinct DNA methylation patterns in cirrhotic liver and hepatocellular carcinoma , 2012, International journal of cancer.

[4]  R. Lovell-Badge,et al.  Betacellulin promotes cell proliferation in the neural stem cell niche and stimulates neurogenesis , 2012, Proceedings of the National Academy of Sciences.

[5]  T. H. van der Kwast,et al.  Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression , 2011, International journal of cancer.

[6]  H. Inoko,et al.  Enforced expression of the transcription factor HOXD3 under the control of the Wnt1 regulatory element modulates cell adhesion properties in the developing mouse neural tube , 2011, Journal of anatomy.

[7]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[8]  M. Fraga,et al.  A promoter DNA demethylation landscape of human hematopoietic differentiation , 2011, Nucleic acids research.

[9]  M. Szyf,et al.  Definition of the landscape of promoter DNA hypomethylation in liver cancer. , 2011, Cancer research.

[10]  G. Pesole,et al.  Developmental factor IRF6 exhibits tumor suppressor activity in squamous cell carcinomas , 2011, Proceedings of the National Academy of Sciences.

[11]  R. Stallings,et al.  Genome‐wide DNA methylation analysis of neuroblastic tumors reveals clinically relevant epigenetic events and large‐scale epigenomic alterations localized to telomeric regions , 2011, International journal of cancer.

[12]  C. Orellana,et al.  Hypermethylation of apoptotic genes as independent prognostic factor in neuroblastoma disease , 2011, Molecular carcinogenesis.

[13]  G. Riggins,et al.  ABI3 ectopic expression reduces in vitro and in vivo cell growth properties while inducing senescence , 2011, BMC Cancer.

[14]  Wei Cao,et al.  The expression of EMP1 is downregulated in oral squamous cell carcinoma and possibly associated with tumour metastasis , 2010, Journal of Clinical Pathology.

[15]  D. Geerts,et al.  Cyclin D1 is a direct transcriptional target of GATA3 in neuroblastoma tumor cells , 2010, Oncogene.

[16]  Y. S. Kim,et al.  Upregulation of SPRR3 Promotes Colorectal Tumorigenesis , 2010, Molecular medicine.

[17]  Hanna Göransson,et al.  Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia. , 2010, Blood.

[18]  R. Siebert,et al.  Array-based DNA methylation profiling of primary lymphomas of the central nervous system , 2009, BMC Cancer.

[19]  C. Buske,et al.  3’UTR mediated regulation of the cyclin D1 proto-oncogene , 2009, Cell cycle.

[20]  G. Selivanova,et al.  p53-dependent inhibition of TrxR1 contributes to the tumor-specific induction of apoptosis by RITA , 2009, Cell cycle.

[21]  K. Gunderson,et al.  Genome-wide DNA methylation profiling using Infinium® assay. , 2009, Epigenomics.

[22]  Marina Bibikova,et al.  A Comprehensive Microarray-Based DNA Methylation Study of 367 Hematological Neoplasms , 2009, PloS one.

[23]  S. Moriya,et al.  Detection of CpG island hypermethylation of caspase‐8 in neuroblastoma using an oligonucleotide array , 2009, Pediatric blood & cancer.

[24]  Miguel Alaminos,et al.  A microarray-based DNA methylation study of glioblastoma multiforme , 2009, Epigenetics.

[25]  T. H. van der Kwast,et al.  Discovery of Novel Hypermethylated Genes in Prostate Cancer Using Genomic CpG Island Microarrays , 2009, PloS one.

[26]  R. Spang,et al.  New insights into the biology and origin of mature aggressive B-cell lymphomas by combined epigenomic, genomic, and transcriptional profiling. , 2009, Blood.

[27]  Michael P. Snyder,et al.  A high throughput embryonic stem cell screen identifies Oct-2 as a bifunctional regulator of neuronal differentiation. , 2009, Genes & development.

[28]  W. Gerald,et al.  Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma , 2009, BMC Cancer.

[29]  Jan Koster,et al.  Cyclin D1 and CDK4 activity contribute to the undifferentiated phenotype in neuroblastoma. , 2008, Cancer research.

[30]  V. Combaret,et al.  Methylation of tumor‐suppressor genes in neuroblastoma: The RASSF1A gene is almost always methylated in primary tumors , 2008, Pediatric blood & cancer.

[31]  Ivo G Gut,et al.  DNA methylation analysis by pyrosequencing , 2007, Nature Protocols.

[32]  L. Hesson,et al.  The Role of RASSF1A Methylation in Cancer , 2007, Disease markers.

[33]  W. Gerald,et al.  Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number. , 2006, Cancer research.

[34]  Hiroyuki Shimada,et al.  International neuroblastoma pathology classification adds independent prognostic information beyond the prognostic contribution of age. , 2006, European journal of cancer.

[35]  G. Rossi,et al.  RASSF1A promoter methylation and 3p21.3 loss of heterozygosity are features of foregut, but not midgut and hindgut, malignant endocrine tumours , 2005, The Journal of pathology.

[36]  W. Gerald,et al.  Clustering of gene hypermethylation associated with clinical risk groups in neuroblastoma. , 2004, Journal of the National Cancer Institute.

[37]  R. Versteeg,et al.  Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'. , 2004, Gene.

[38]  Brad T. Sherman,et al.  DAVID: Database for Annotation, Visualization, and Integrated Discovery , 2003, Genome Biology.

[39]  Rogier Versteeg,et al.  Rearrangements and increased expression of cyclin D1 (CCND1) in neuroblastoma , 2003, Genes, chromosomes & cancer.

[40]  J. Minna,et al.  The RASSF1A Tumor Suppressor Blocks Cell Cycle Progression and Inhibits Cyclin D1 Accumulation , 2002, Molecular and Cellular Biology.

[41]  U. Suter,et al.  Embryonic expression of epithelial membrane protein 1 in early neurons. , 1999, Brain research. Developmental brain research.

[42]  K K Matthay,et al.  The International Neuroblastoma Pathology Classification (the Shimada system) , 1999, Cancer.

[43]  R. Chetty,et al.  Cyclin D1 and human neoplasia. , 1998, Molecular pathology : MP.

[44]  G. E. Thomas.  Resampling‐Based Multiple Testing: Examples and Methods for p‐Value Adjustment , 1994 .

[45]  F. Berthold,et al.  Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. , 1993, Progress in clinical and biological research.

[46]  S. S. Young,et al.  Resampling-Based Multiple Testing: Examples and Methods for p-Value Adjustment , 1993 .

[47]  Peter A. Jones,et al.  Epigenetics in cancer. , 2010, Carcinogenesis.

[48]  H. Carén,et al.  Identification of epigenetically regulated genes that predict patient outcome in neuroblastoma , 2011, BMC Cancer.

[49]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .